Amir Mortazavi, MD

College

College of Medicine

Department/Division

Internal Medicine

Academic Title

Professor

Research Program

Molecular Carcinogenesis and Chemoprevention

Research Interest

Cancer ● Urinary Bladder Cancer ● Leukemia, Myeloid, Acute ● Leukemia, Lymphocytic, Chronic, B-Cell ● Weight Loss ● Colorectal Cancer ● Carcinoma, Renal Cell ● Anorexia ● Leukemia, Promyelocytic, Acute

Amir Mortazavi, MD, is a member of the Molecular Carcinogenesis and Chemoprevention Program at the OSUCCC – James, where his research focuses on epigenetic modifications and experimental therapeutics for genitourinary cancers.

One of his recent research projects suggests that sorafenib, an oral multikinase inhibitor, could have off-target effects on cytokine-induced signal transduction in immune effector cells.

Dr. Mortazavi has co-authored many articles in well-respected publications, including Cancer Chemotherapy and Pharmacology, Journal of Immunology, Journal of Proteome Research and Journal of Magnetic Resonance Imaging.

Office Location

A441 Starling Loving Hall

320 W 10th Ave, Columbus, OH 43210

614-293-2886

614-293-7525

mortazavi.1@osu.edu

Publications

Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study.

Martínez Chanzá N, Xie W, Asim Bilen M, Dzimitrowicz H, Burkart J, Geynisman DM, Balakrishnan A, Bowman IA, Jain R, Stadler W, Zakharia Y, Narayan V, Beuselinck B, McKay RR, Tripathi A, Pachynski R, Hahn AW, Hsu J, Shah SA, Lam ET, Rose TL, Mega AE, Vogelzang N, Harrison MR, Mortazavi A, Plimack ER, Vaishampayan U, Hammers H, George S, Haas N, Agarwal N, Pal SK, Srinivas S, Carneiro BA, Heng DYC, Bosse D, Choueiri TK, Harshman LC

Lancet Oncol in press 02/28/2019
Phase 1 Immunotherapy Trial with Two Chimeric HER-2 B-Cell Peptide Vaccines emulsified in Montanide ISA 720VG and nor-MDP Adjuvant in Advanced Solid Tumors.

Bekaii-Saab T, Wesolowski R, Ahn DH, Wu C, Mortazavi A, Lustberg MB, Ramaswamy B, Fowler J, Wei L, Overholser J, Kaumaya PTP

Clin Cancer Res in press 02/25/2019
Phase 1 Immunotherapy Trial with Two Chimeric HER-2 B-Cell Peptide Vaccines emulsified in Montanide ISA 720VG and nor-MDP Adjuvant in Advanced Solid Tumors.

Bekaii-Saab T, Wesolowski R, Ahn DH, Wu C, Mortazavi A, Lustberg MB, Ramaswamy B, Fowler J, Wei L, Overholser J, Kaumaya PTP

Clin Cancer Res in press 02/25/2019
Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes.

Grivas P, Mortazavi A, Picus J, Hahn NM, Milowsky MI, Hart LL, Alva A, Bellmunt J, Pal SK, Bambury RM, O'Donnell PH, Gupta S, Guancial EA, Sonpavde GP, Faltaos D, Potvin D, Christensen JG, Chao RC, Rosenberg JE

Cancer 125 533-540 02/15/2019
Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations.

Pal SK, Rosenberg JE, Hoffman-Censits JH, Berger R, Quinn DI, Galsky MD, Wolf J, Dittrich C, Keam B, Delord JP, Schellens JHM, Gravis G, Medioni J, Maroto P, Sriuranpong V, Charoentum C, Burris HA, Grünwald V, Petrylak D, Vaishampayan U, Gez E, De Giorgi U, Lee JL, Voortman J, Gupta S, Sharma S, Mortazavi A, Vaughn DJ, Isaacs R, Parker K, Chen X, Yu K, Porter D, Graus Porta D, Bajorin DF

Cancer Discov 8 812-821 07/01/2018
Effects of a Group-Mediated Exercise and Dietary Intervention in the Treatment of Prostate Cancer Patients Undergoing Androgen Deprivation Therapy: Results From the IDEA-P Trial.

Focht BC, Lucas AR, Grainger E, Simpson C, Fairman CM, Thomas-Ahner JM, Buell J, Monk JP, Mortazavi A, Clinton SK

Ann Behav Med 52 412-428 04/19/2018
A Potential Role for Adjuvant Chemotherapy and Radiotherapy for Patients With High-Risk Bladder Cancer Treated With Cystectomy in the United States.

Diaz DA, Mortazavi A, Lee CT

JAMA Surg 153 e174592 01/17/2018
Cruciferous Vegetables, Isothiocyanates, and Bladder Cancer Prevention.

Abbaoui B, Lucas CR, Riedl KM, Clinton SK, Mortazavi A

Mol Nutr Food Res 62 e1800079 01/01/2018
Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC).

Monk P, Liu G, Stadler WM, Geyer S, Huang Y, Wright J, Villalona-Calero M, Wade J, Szmulewitz R, Gupta S, Mortazavi A, Dreicer R, Pili R, Dawson N, George S, Garcia JA

Invest New Drugs 36 919-926 01/01/2018
Multicenter Phase 2 Trial of Gemcitabine, Carboplatin, and Sorafenib in Patients With Metastatic or Unresectable Transitional-Cell Carcinoma.

Hurwitz ME, Markowski P, Yao X, Deshpande H, Patel J, Mortazavi A, Donadio A, Stein MN, Kelly WK, Petrylak DP, Mehnert JM

Clin Genitourin Cancer 16 437-444.e6 01/01/2018
A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas.

Sborov DW, Canella A, Hade EM, Mo X, Khountham S, Wang J, Ni W, Poi M, Coss C, Liu Z, Phelps MA, Mortazavi A, Andritsos L, Baiocchi RA, Christian BA, Benson DM, Flynn J, Porcu P, Byrd JC, Pichiorri F, Hofmeister CC

Leuk Lymphoma 58 2310-2318 10/01/2017
Analytic validation and real-time clinical application of an amplicon-based targeted gene panel for advanced cancer.

Wing MR, Reeser JW, Smith AM, Reeder M, Martin D, Jewell BM, Datta J, Miya J, Monk JP, Mortazavi A, Otterson GA, Goldberg RM, VanDeusen JB, Cole S, Dittmar K, Jaiswal S, Kinzie M, Waikhom S, Freud AG, Zhou XP, Chen W, Bhatt D, Roychowdhury S

Oncotarget 8 75822-75833 09/29/2017
Non-invasive quantification of tumour heterogeneity in water diffusivity to differentiate malignant from benign tissues of urinary bladder: a phase I study.

Nguyen HT, Shah ZK, Mortazavi A, Pohar KS, Wei L, Jia G, Zynger DL, Knopp MV

Eur Radiol 27 2146-2152 05/01/2017
The impact of cruciferous vegetable isothiocyanates on histone acetylation and histone phosphorylation in bladder cancer.

Abbaoui B, Telu KH, Lucas CR, Thomas-Ahner JM, Schwartz SJ, Clinton SK, Freitas MA, Mortazavi A

J Proteomics 156 94-103 01/06/2017
Does the Renal Parenchyma Adjacent to the Tumor Contribute to Kidney Function? A Critical Analysis of Glomerular Viability in Partial Nephrectomy Specimens.

Khemees TA, Lam ET, Joehlin-Price AS, Mortazavi A, Phillips GS, Shabsigh A, Sharp DS, Zynger DL

Urology 87 114-9 01/01/2016
Biomodulation of capecitabine by paclitaxel and carboplatin in advanced solid tumors and adenocarcinoma of unknown primary.

Mikhail S, Lustberg MB, Ruppert AS, Mortazavi A, Monk P, Kleiber B, Villalona-Calero M, Bekaii-Saab T

Cancer Chemother Pharmacol 76 1005-12 11/01/2015
The Raf Kinase Inhibitor Sorafenib Inhibits JAK-STAT Signal Transduction in Human Immune Cells.

Martin Del Campo SE, Levine KM, Mundy-Bosse BL, Grignol VP, Fairchild ET, Campbell AR, Trikha P, Mace TA, Paul BK, Jaime-Ramirez AC, Markowitz J, Kondadasula SV, Guenterberg KD, McClory S, Karpa VI, Pan X, Olencki TE, Monk JP, Mortazavi A, Tridandapani S, Lesinski GB, Byrd JC, Caligiuri MA, Shah MH, Carson WE 3rd

J Immunol 195 1995-2005 09/01/2015
The Raf Kinase Inhibitor Sorafenib Inhibits JAK-STAT Signal Transduction in Human Immune Cells.

Martin Del Campo SE, Levine KM, Mundy-Bosse BL, Grignol VP, Fairchild ET, Campbell AR, Trikha P, Mace TA, Paul BK, Jaime-Ramirez AC, Markowitz J, Kondadasula SV, Guenterberg KD, McClory S, Karpa VI, Pan X, Olencki TE, Monk JP, Mortazavi A, Tridandapani S, Lesinski GB, Byrd JC, Caligiuri MA, Shah MH, Carson WE 3rd

J Immunol 195 1995-2005 09/01/2015
Do amount of variant differentiation and mitotic rate in bladder cancer change with neoadjuvant chemotherapy?

Shen HM, D'Souza AM, Green IF, Pohar KS, Mortazavi A, Zynger DL

Hum Pathol 46 1367-75 09/01/2015
Prediction of chemotherapeutic response in bladder cancer using K-means clustering of dynamic contrast-enhanced (DCE)-MRI pharmacokinetic parameters.

Nguyen HT, Jia G, Shah ZK, Pohar K, Mortazavi A, Zynger DL, Wei L, Yang X, Clark D, Knopp MV

J Magn Reson Imaging 41 1374-82 05/01/2015
Proteomic profiling identifies specific histone species associated with leukemic and cancer cells.

Singh R, Harshman SW, Ruppert AS, Mortazavi A, Lucas DM, Thomas-Ahner JM, Clinton SK, Byrd JC, Freitas MA, Parthun MR

Clin Proteomics 12 22 01/01/2015
Improving bladder cancer imaging using 3-T functional dynamic contrast-enhanced magnetic resonance imaging.

Nguyen HT, Pohar KS, Jia G, Shah ZK, Mortazavi A, Zynger DL, Wei L, Clark D, Yang X, Knopp MV

Invest Radiol 49 390-5 06/01/2014

See Full List

Back to Researcher Search

Find a Researcher
Find a Clinical Trial

Please enter a keyword (i.e. Name, Research Interest) or choose a Research Program

By Name or Keyword

OR

By Research Program

Please enter a keyword (i.e. Name, Cancer Type) or choose a Principle Investigator

Amir Mortazavi, MD

College

Department/Division

Academic Title

Research Program

Research Interest

Office Location

Publications

Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study.

Phase 1 Immunotherapy Trial with Two Chimeric HER-2 B-Cell Peptide Vaccines emulsified in Montanide ISA 720VG and nor-MDP Adjuvant in Advanced Solid Tumors.

Phase 1 Immunotherapy Trial with Two Chimeric HER-2 B-Cell Peptide Vaccines emulsified in Montanide ISA 720VG and nor-MDP Adjuvant in Advanced Solid Tumors.

Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes.

Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations.

Effects of a Group-Mediated Exercise and Dietary Intervention in the Treatment of Prostate Cancer Patients Undergoing Androgen Deprivation Therapy: Results From the IDEA-P Trial.

A Potential Role for Adjuvant Chemotherapy and Radiotherapy for Patients With High-Risk Bladder Cancer Treated With Cystectomy in the United States.

Cruciferous Vegetables, Isothiocyanates, and Bladder Cancer Prevention.

Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC).

Multicenter Phase 2 Trial of Gemcitabine, Carboplatin, and Sorafenib in Patients With Metastatic or Unresectable Transitional-Cell Carcinoma.

A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas.

Analytic validation and real-time clinical application of an amplicon-based targeted gene panel for advanced cancer.

Non-invasive quantification of tumour heterogeneity in water diffusivity to differentiate malignant from benign tissues of urinary bladder: a phase I study.

The impact of cruciferous vegetable isothiocyanates on histone acetylation and histone phosphorylation in bladder cancer.

Does the Renal Parenchyma Adjacent to the Tumor Contribute to Kidney Function? A Critical Analysis of Glomerular Viability in Partial Nephrectomy Specimens.

Biomodulation of capecitabine by paclitaxel and carboplatin in advanced solid tumors and adenocarcinoma of unknown primary.

The Raf Kinase Inhibitor Sorafenib Inhibits JAK-STAT Signal Transduction in Human Immune Cells.

The Raf Kinase Inhibitor Sorafenib Inhibits JAK-STAT Signal Transduction in Human Immune Cells.

Do amount of variant differentiation and mitotic rate in bladder cancer change with neoadjuvant chemotherapy?

Prediction of chemotherapeutic response in bladder cancer using K-means clustering of dynamic contrast-enhanced (DCE)-MRI pharmacokinetic parameters.

Proteomic profiling identifies specific histone species associated with leukemic and cancer cells.

Improving bladder cancer imaging using 3-T functional dynamic contrast-enhanced magnetic resonance imaging.

OR

OR

Search for Clinical Trials

Find a Scientific Publication

Amir Mortazavi, MD

College

Department/Division

Academic Title

Research Program

Research Interest

Office Location

Publications

Related Links

OR

OR

Search for Clinical Trials

Find a Scientific Publication